Calliditas Therapeutics AB (CALT) Stock Analyst Earnings Estimates
NASDAQ:CALT - Nasdaq - US13124Q1067 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 229.347M 26,141.08% | 802.879M 250.07% | 1.207B 50.32% | 2.01B 66.54% | 3.275B 62.94% | 4.676B 42.78% | 6.128B 31.05% | 6.353B 3.67% | 4.699B -26.03% | 3.844B -18.20% | 3.603B -6.27% | |
| EBITDA YoY % growth | N/A -20.10% | -401.897M 17.40% | -341.857M 14.94% | 124.94M 136.55% | 1.065B 752.41% | 2.036B 91.17% | 5.303B 160.46% | 5.682B 7.15% | 3.944B -30.59% | 2.055B -47.90% | N/A | |
| EBIT YoY % growth | -524.605M -37.26% | -414.81M 20.93% | -390.583M 5.84% | 129.78M 133.23% | 1.007B 675.93% | 1.814B 80.14% | 3.332B 83.68% | 3.265B -2.01% | 2.324B -28.82% | 1.727B -25.69% | 1.7B -1.56% | |
| Operating Margin | -228.74% | -51.67% | -32.36% | 6.46% | 30.75% | 38.79% | 54.37% | 51.39% | 49.46% | 44.93% | 47.18% | |
| EPS YoY % growth | N/A -39.33% | N/A 20.70% | -17.25 -14.44% | 4.66 127.00% | 38.16 719.41% | 79.65 108.75% | 203.73 155.79% | 278.63 36.76% | N/A | N/A | N/A |
All data in SEK
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | 2.49 139.91% | 6.73 1,095.67% |
| Revenue Q2Q % growth | 547.4M 85.82% | 697.1M 54.38% |
| EBITDA Q2Q % growth | 87.55M 722.61% | 242.74M 361.86% |
| EBIT Q2Q % growth | 67.692M 142.42% | 208.32M 398.80% |
All data in SEK
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | -1.75 48.54% | -0.62 | -1.13 | -181.66% |
| Q1 2024 Q2Q % growth | -9.12 -31.52% | -3.36 | -5.76 | -171.73% |
| Q4 2023 Q2Q % growth | -0.68 -385.71% | -3.54 | 2.86 | 80.89% |
| Q3 2023 Q2Q % growth | -6.24 -1,747.06% | -0.58 | -5.66 | -979.13% |
| Q2 2023 Q2Q % growth | -3.40 52.76% | -4.41 | 1.01 | 22.90% |
| Q1 2023 Q2Q % growth | -6.94 | -3.48 | -3.46 | -99.31% |
| Q4 2022 Q2Q % growth | -0.14 98.33% | -3.50 | 3.36 | 96.03% |
| Q3 2022 Q2Q % growth | -0.34 | -6.18 | 5.84 | 94.53% |
| Q2 2022 Q2Q % growth | -7.19 | -8.66 | 1.46 | 16.91% |
| Q4 2021 Q2Q % growth | -8.33 -8.26% | -7.61 | -0.71 | -9.35% |
| Q4 2020 Q2Q % growth | -477.32% | -7.69 | % |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 559.78M 107.80% | 458.71M | 101.07M | 22.03% |
| Q1 2024 Q2Q % growth | 295.481M 54.42% | 379.04M | -83.559M | -22.04% |
| Q4 2023 Q2Q % growth | 451.561M 5.25% | 364.28M | 87.281M | 23.96% |
| Q3 2023 Q2Q % growth | 294.592M 13.28% | 376.01M | -81.418M | -21.65% |
| Q2 2023 Q2Q % growth | 269.384M 320.60% | 286.08M | -16.696M | -5.84% |
| Q1 2023 Q2Q % growth | 191.352M 284.75% | 269M | -77.648M | -28.87% |
| Q4 2022 Q2Q % growth | 429.042M 1,276.02% | 196.22M | 232.822M | 118.65% |
| Q3 2022 Q2Q % growth | 260.056M 31.23% | 144.72M | 115.336M | 79.70% |
| Q2 2022 Q2Q % growth | 64.047M | 53.045M | 11.002M | 20.74% |
| Q4 2021 Q2Q % growth | 31.18M 7,695.00% | 31.18M | % | |
| Q1 2021 Q2Q % growth | -100.00% | % | ||
| Q4 2020 Q2Q % growth | 400K -99.14% | 12.129M | -11.729M | -96.70% |
| Q2 2020 Q2Q % growth | -100.00% | % | ||
| Q4 2019 Q2Q % growth | 46.586M | 199.204M | -152.618M | -76.61% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -0.67% | 61.18% | -0.67% | -20.69% |
| Revenue | 0% | 2.11% | 0% | -5.1% |